Topiramate in migraine prophylaxis: data from a pooled analysis and open-label extension study

被引：9

作者：

Bussone, G ^{[1
]}

Usai, S ^{[1
]}

D'Amico, D ^{[1
]}

机构：

[1] C Besta Natl Neurol Inst, Headaches & Cerebrovasc Disorders Unit, I-20133 Milan, Italy

来源：

NEUROLOGICAL SCIENCES | 2006年 / 27卷 / Suppl 2期

关键词：

migraine; topiramate; prophylaxis; clinical trial; pooled analysis; open-label extension phase;

D O I：

10.1007/s10072-006-0593-z

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Topiramate is approved for the preventive treatment of migraine in several countries based on the results of three large randomised, double-blind studies that showed that this compound was significantly more effective than placebo in migraine prophylaxis. We review the results of two studies: one which pooled data from the three controlled double-blind trials using 100 mg/day of topiramate, and an open-label extension of two of these trials in which patients received different topiramate doses for an eight-month maintenance period. The overall results confirm that topiramate is effective in reducing migraine frequency, and has a satisfactory tolerability profile.

引用

页码：S159 / S163

页数：5